Clin2
NCT05793151Possibly a fitRecruiting

Guided care to start cancer treatment on time after surgery

Head and Neck CancerHead and Neck Squamous Cell CarcinomaOropharynx CancerOral Cavity CancerLarynx Cancer

Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.

This trial tests a navigation program (help from a care coordinator) versus usual care to help people start the recommended “next-step” treatments (like radiation, sometimes with chemo) on time after surgery. It’s for certain stages of squamous cell cancer in the head and neck area where late treatment could matter.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
532 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have squamous cell cancer in the mouth, throat (oropharynx/hypopharynx/larynx), sinuses, nasal cavity, or an unknown primary site.
  • Your cancer stage (based on exams/scans) is more advanced: T3–T4 and/or N1 or higher.
  • You have not had radiation therapy for head-and-neck squamous cell cancer before (in the main treatment or after treatment).
  • You plan curative-intent surgery at one of the participating study centers.
  • After surgery, you’re expected to need post-surgery treatment (usually radiation, with or without chemo) because your final pathology may show higher-risk features like T3–T4, N1+ nodes, nerve invasion, or blood/lymph vessel invasion.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05993858Not yet recruiting· Phase 2
Immune therapy and targeted therapy before surgery for head and neck cancer

This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.

Wuhan, Hebei
NCT07528495Recruiting· Phase 2/Phase 3
Skipping neck radiation for oral cancer after surgery

This trial tests whether patients with early-stage oral cancer who have surgery and lymph-node removal can skip radiation to the neck if certain favorable conditions are met. The goal is to reduce side effects like difficulty swallowing while keeping cancer control strong.

Jhajjar, Haryana
NCT05674396Recruiting· Phase 2
Short-course radiation to ease symptoms from head and neck cancer

This Phase 2 trial tests a specific, shorter type of focused radiation to help relieve symptoms from head and neck squamous cell carcinoma. It compares two radiation timing/planning approaches to see which better improves comfort and quality of life.

Houston, Texas
NCT06127784Recruiting
Survivorship program for head and neck cancer follow-up

This trial tests a new program to help people who finished treatment for head and neck cancer stay on track with follow-up care. You may be able to join if you completed treatment 3 to 6 months ago and your cancer has not spread.

London, Ontario
NCT07241273Not yet recruiting
Guided neck radiation for one-sided throat cancer

This trial tests a new way to guide radiation treatment for a type of throat cancer that is on one side only. The goal is to see if using a special scan (SPECT-CT) to map lymph drainage can help doctors decide how to treat the neck more precisely and reduce side effects.

Brest
NCT06578871Not yet recruiting· Phase 2
Surgery and reduced radiation for neck cancer of unknown origin

This study tests whether giving less radiation after surgery is as effective as standard radiation for people with a specific type of neck cancer that started somewhere unknown. It aims to reduce side effects while keeping the cancer from coming back.

Adelaide, South Australia

Hear when a new Head and Neck Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.